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I. INTRODUCTION

Every day, the average consumer encounters trademarks through a
product’s or service’s names, either through use or via advertisements
indicating the source of origin and the product or services’ quality.
According to the conventional justifications for trademark protection, a
trademark differentiates the products to eliminate consumer confusion and
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to assure consumers of the uniform quality of the trademarked product.
Earlier, the trademarks were restricted to the word, device, label or any
other visual identifier of the company. Nowadays, considering the
trademark’s potential to enhance the brand’s equity, trademarks have
expanded to include nontraditional features, such as sound, shape, smell,
color, hologram, position mark, or taste mark. Hence, the trademarks not
only assure consumers of good’s or service’s quality but are also used as
a marketing tool. In this way, trademarks serve four primary functions:
(1) indicating the source of origin, (2) distinguishing the goods and
services from others, (3) assuring the consumers of the quality of the
product, and (4) advertising the product in the market.
Like other consumer-oriented fields, pharmaceutical companies use
trademarks as a brand strategy to help consumers identify their products
as a familiar choice. The pharmaceutical sector is a high-technology,
knowledge-intensive, and heavily regulated industry that includes the
distinctive drug nomenclature system. Since a drug is identified by three
names: a chemical name, generic name and proprietary name. In this
sector, a brand name, or proprietary name, differentiates the product from
other available alternatives in the market, thereby reducing the
consumer’s search cost while increasing their loyalty.
The pharmaceutical industry has a two-tier structure: branded and
generic. The first and the larger tier is comprised of multinational entities
and large companies that invest majorly in the research and development
(R&D), allowing them to hold the majority of patents in the sector. The
second tier is majorly comprised of smaller firms that manufacture offpatented products or are under license to a patent-holder and hold a
smaller share in the patent segment. Through this two-tier system, final
products are marketed as branded, generic, and branded-generic. Here,
when a trademark is assigned to a patented drug by the innovator drug
company it is referred as a branded drug, whereas a generic drug product
is marketed solely by its generic name. On the contrary when trademarks
are applied to generic drugs, it is known and marketed as branded-generic
products.
As a marketing tool, trademarks are used as a part of sales strategy
by the innovator drug companies that establish the brand name during
patent protection. After a patent expires, a branded drug is substituted with
a generic drug so that a prescription drug having the same active
ingredient is available in the market for consumers. In the brandedmedicine market, trademarks play an important role, allowing consumers
to identify and differentiate between all available options. The definition
of consumer changes with the nature of the medication—prescription-
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based or over-the-counter (OTC). Consumers can only obtain prescription
drugs by showing a prescription written by a medical practitioner,
whereas consumers may purchase OTC drugs directly with no restrictions.
Hence, a medical practitioner gets to choose the marketed prescription
drug for their patients, whereas a consumer chooses their OTC drugs.
Therefore, the availability of myriad alternative brands with similar
chemical composition may create artificial product differentiation, hence
confusion in product selection.
In this context, the authors of this paper have analyzed the divergent
views of legal scholars on the use of trademarks for product differentiation
of formulaically similar or bioequivalent products. There are two general
views among these scholars: protectionist and restrictionist views.
Scholars with a protectionist view support trademark protection for
products that are formulaically similar or bioequivalent in nature, whereas
legal scholars with a restrictionism approach have criticized its persuasive
effects on consumers. For comprehensive understanding, the marketing
strategies adopted by the branded drug and branded-generic
manufacturers have also been studied, that reflects on how companies
utilize trademarks to market a single formulation in different ways.
Thereby encouraging consumers to ask for advertised medicines (branded
drugs) over substitutable cheaper generic drugs. Consequently, widening
the demand gap between the branded and generic drugs, especially where
the marketed drug is approved by the Food and Drug Administration
(FDA) on the set parameters of quality and safety. Further, this paper
analyzes the effect of such trademark expansion in the branded
pharmaceutical sector from the United States’ market practices and
regulatory perspectives. Similarly, to study the impact on market and
consumer health through the lens of the branded-generic sector, this paper
analyzes the regulatory interventions in India and compares them with the
scholars’ views.
This paper is divided into four segments—the first segment details
legal scholars’ views on using trademarks to differentiate chemically
equivalent products. The second explains the drug nomenclature system
to understand the scientific equation of branded and branded-generic with
generic naming of a drug. The third highlights industry practices and
regulations, if any, in the branded and branded-generic markets of the
United States and India, respectively. Finally, the paper concludes with
the solutions suggested by legal scholars and regulatory authorities
towards resolving the challenges arising from using trademarks for similar
drugs.
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II. RATIONALE FOR TRADEMARK PROTECTION: DIFFERENTIATION
VERSUS ARTIFICIAL DIFFERENTIATION
Trademark law has evolved from tort law, protecting consumers
from unfair competition and deception. 1 As a result, the conventional
justification for trademark protection is two-pronged: to ensure that
trademarks minimize consumer confusion and that manufacturers
maintain consistent product quality. Gradually, with the development of
means of communication, trademarks’ significance and subject matter of
protection substantially broadened. The value of modern trademarks
began to rest in their selling power. Acting as a link between the owner
and the consumers, trademarks are ultimately based on the quality and
merit of the goods or services. 2
At the primary level, a trademark is a distinctive mark in the form of
name, packaging, label, device, or other physical feature, that indicates a
particular product’s origin and distinguishes it from others. 3 In doing so,
the trademark advertises the product and enables consumers to
differentiate it between the alternate goods available in the market and
also reduces the search cost. In this way, the trademark balances the
interest of proprietors and consumers. Nevertheless, there still subsists a
scholarly debate regarding the scope of trademark protection and its
impact on consumers’ interest.
Companies essentially use trademarks as an advertising function,
which helps differentiate a product and establish its position in the
competitive market. According to legal scholars, through product
differentiation, companies can carve out a separate market for their
products. Companies can even manipulate the demand, price, and output
of a product—within legal limits—by channeling the advertising function
of trademarks. 4 In the view of scholars with restrictionism approach,
trademarks are being used for persuasion instead of identification. 5 Some
scholars oppose this approach, arguing that consumers rely on trademarks
as informational devices and nothing more. Therefore, trademarks rather

1. Mark McKenna, The Normative Foundations of Trademark Law, 82 NOTRE DAME L. R EV.
1839 (2007).
2. Frank I. Schechter, The Rational Basis of Trademark Protection, 40 HARV. L. R EV. 813,
830–31 (1927).
3. J. THOMAS MCC ARTHY, MCC ARTHY ON TRADEMARKS AND UNFAIR C OMPETITION, (Clark
Boardman Callaghan 5th ed. 1996).
4. EDWARD C HAMBERLIN, THEORY OF MONOPOLISTIC C OMPETITION: A R E-ORIENTATION OF
THE THEORY OF VALUE (Harvard University Press 1933).
5. Ralph Brown, Advertising and the Public Interest: Legal Protection of Trade Symbols, 57
YALE L.J. 1165, 1171 (1948).
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encourage manufactures to improve the quality of their products and deter
imitators from free-riding on the goodwill of the producers. 6 It is worth
noting that, while dismissing the observations of restrictionist scholars on
the persuasive function and its influence on consumers’ choice, the
scholars with protectionist view base their arguments on the consumer
rationale, i.e., the significance of trademarks from the quality perspective.
Although consumers may not be interested in the chemical composition
during product selection, they may be willing to pay a premium for quality
assurance. 7 The scholars support trademark protection also from an
economic perspective, that it reduces the consumers’ “search cost” in the
competitive drug market. 8
In this instance, it is relevant to highlight the concept of the two-fold
nature of trademark distinctiveness, as explained by Barton Beebe. The
two-fold nature can be observed as absolute distinctiveness, that indicates
the distinctiveness as to the source of origin, and differential
distinctiveness, which refers to an informational effect that causes
consumers to perceive a particular trademark-protected good as different
from the others. 9 Considering both the producers’ incentive and ability to
manipulate consumers’ will through advertisement, Beebe differed from
Landes and Posner’s economic justification, who supports the trademark
protection from an economic perspective, that trademarks helps consumer
by reducing their search cost. 10 In the same line, other scholars, like
Dorfman and Steiner, identified that a trademark’s advertising function
creates product differentiation, leading to higher prices. 11
The debate about actual and artificial product differentiation
intensifies when trademarks differentiate chemically similar goods,
especially by the pharmaceutical industry to differentiate a branded drug
from a bioequivalent generic drug. In this context, scholars Roger
Feldman and Felix Lobo observed that if trademarks reduce search costs
but increase product differentiation, they may not benefit consumers. 12
When applied to pharmaceutical products, the chance of confusion due to
6. William M. Landes & Richard A. Posner, Trademark Law: An Economic Perspective, 30
J.L. & ECON., 265, 269 (1987).
7. Id. at 275.
8. Mark A. Lemley, The Modern Lanham Act and the Death of Common Sense, 108 YALE L.J.
1687, 1690 (1999).
9. Barton Beebe, Search and Persuasion in Trademark Law, 103 MICH. L. R EV. 2020 (2005).
10. Id. at 2024
11. Robert Dorfman & Peter O. Steiner, Optimal Advertising and Optimal Quality, 44 AM.
ECON. R EV. 826 (1954).
12. Roger Feldman & Felix Lobo, Competition in Prescription Drug Markets: The Roles of
Trademarks, Advertising, and Generic Names, 14 EUR. J. HEALTH & ECON. 667 (2013).
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artificial product differentiation increases. They supported the idea of
letting companies use international nonproprietary names (INN), or
generic names, to minimize the search costs and product differentiation
that may lead to unquestionable consumer benefits. Since, in this way, the
private sector would underinvest in common nomenclature because each
firm would pay attention only to the effect of language on search costs for
its product. 13
In the pharmaceutical industry, when the patent for a branded drug
expires, the authorities introduce a generic name that doctors can apply to
any generic equivalent of that drug. If a doctor uses the generic name on
a prescription, the pharmacist is free to substitute any appropriate drug,
presumably the cheapest one. However, once a doctor prescribes a drug
using a brand name, the pharmacist must provide that drug and cannot
substitute it with a generic alternative. 14 The influence of advertising and
promotion of branded drugs generally led consumers to believe that
trademarked medications were distinct from one another and superior to
generic drugs. 15 While resolving this problem, Hannah Brennan proposed
to replace trademarks with manufacturers’ marks, that while performing
the function of trademark as origin indicator will not be artificially
differentiating the bio-equivalent drugs. 16 Following the similar
argument, the scholar Jeremy Greene highlighted the negative
implications of the practice of using trade-dress that visibly differentiates
between the branded and generic drugs, thereby raising doubts in the mind
of the patients about the quality of generic drugs. 17 Thereby he suggested
to reduce artificial product differentiation by introducing a consistent and
organized system of pill appearance to increase patient adherence, that
will further reduce the complexity of medication errors, and thereby, he
also encouraged the rational use of bioequivalent generic drugs. 18
The later part of this paper highlights the strategies that are devised
by the manufacturers to sustain upward growth and profitability through
product differentiation. More and more companies, including both
research-based and generic companies, are joining the race to develop
differentiated drug products. Trademarks are being used as a tool for

13. Id. at 660
14. Id. at 673
15. Hannah Brennan, The Cost of Confusion: The Paradox of Trademarked Pharmaceuticals,
22 MICH. TELECOMM. & TECH. L. R EV. 1 (2015).
16. Id. at 20.
17. Jeremy A. Greene, The materiality of the brand: Form, function, and the pharmaceutical
trademark, 29(2) Int. J. Technol., 210-226 (2013).
18. Id. at 219.
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artificial product differentiation: As a marketing strategy, companies use
multiple trademarks to differentiate branded and generic drugs, even
though both have the same composition and origin.
In marketing language, this practice is identified as product line
extension that forms a part of the life cycle management of a molecule
facing extinction owing to generic competition. The next section
elaborates upon the nomenclature of a drug, followed by an analysis of
the impact of line extension strategy adopted by the innovator drug
companies and branded-generic companies that create artificial product
differentiation.
III. AN OVERVIEW OF PHARMACEUTICAL NAMING SYSTEM
“A name is a necessity. It distinguishes one thing from dissimilar
things. A name also distinguishes one thing from other similar things but
not the same.”
– Nelson M Gampfer, National Pharmaceutical Council 1961.
Therapeutic use of the same drugs for different medical conditions
has been in existence since time immemorial. Until mid-nineteenth
century, the drugs were dispensed by pharmacists in the form of raw
materials that met pharmacopeial standards. 19 The area of activities were
clearly defined, where the role of a manufacturers was restricted to the
supply of bulk chemicals to the pharmacist, and after careful evaluation
the final drug formulation were being prepared and dispensed by the
pharmacist to the patients. Later, with the development of the synthetic
dyestuffs industry, advertisement became a common practice. 20
Regulations have evolved gradually over time. Since the chemical names
of these drugs were complex and difficult to remember, it was necessary
to develop simple names that would help to identify the chemical
composition of drugs. Hence, it led to the development of nonproprietary
names. 21
The practice of naming can be traced back to 1784 in Germany,
where a pharmacopeia was created by compiling and publishing the
catalogs of drugs, Subsequently, pharmacopeias were adopted for uniform

19. Alan Wayne Jones, Early drug discovery and the rise of pharmaceutical chemistry, 3(6)
Drug Test Anal. 337-44 (2011).
20. Jan R. McTavish, Aspirin in Germany: The Pharmaceutical Industry and the
Pharmaceutical Profession, 29 P HARM. HIST. 103 (1987).
21. WORLD HEALTH ORGANIZATION, GUIDANCE ON THE USE OF INTERNATIONAL
NONPROPRIETARY NAMES (INNS) FOR P HARMACEUTICAL S UBSTANCES (2017).
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identification of the medicines in many countries. Different countries
published their own pharmacopeias like British Approved Names (BANs)
and United States Adopted Names (USAN). Given the existence of
different national nomenclature systems, the World Health Organization
(WHO) harmonized the varied structure of the national nomenclature
committees to standardize drug names. 22 WHO developed and formally
established its nomenclature program in 1953 when its Experts
Committee for the Unification of Pharmacopoeias drew up a plan to create
a standard nomenclature for medicines, resulting in the publication of the
first International Nonproprietary Names (INN) list for pharmaceutical
substances.
INN is a foundational system that exchanges and updates
information among health professionals worldwide. The names identified
by INN are globally recognized and available in the public domain. WHO,
together with the World Intellectual Property Organization (WIPO),
encourages national offices to follow these recommendations when
examining drug trademarks. 23 The goal behind the INN is to avoid a
multiplicity of names and the resulting confusion and difficulty in
identifying a prescribed medicine, dispensing it to the patient, and
controlling drugs moving in international commerce. 24 The drug
regulatory authority along with trademark authority must consider this
objective behind the creation of INN and take necessary measures to
avoid probable confusion that may arise from the use of similar propritiry
names.
Active Pharmaceutical Ingredients (API) can be simultaneously
identified by three names: a chemical, generic, and brand name. A
chemical name is a scientific name based on the compound’s chemical
structure that is complex and lengthy, which is why they are not used for
marketing purposes. A generic name refers to the nonproprietary name of
API; therefore, it is public property. As a consequence, whenever a new
terminology becomes an INN, it is no longer available for exclusive
ownership in the form of a trademark. A trademark or proprietary name
can be any word or combination of words that doesn’t represent a common
medicinal name.

22. Kuhu Tiwari & Niharika Sahoo Bhattacharya, Pharmaceutical Trademarks: An Evaluation
of Regulatory Intricacies and Challenges, 15 J. INTELL. P ROP. L. AND P RAC. 738 (2020).
23. World Intell. Prop. Org., Standing Comm. on the Law of Trademarks, Industrial Designs
and Geographical Indications, Marks and International Nonproprietary Names for Pharmaceutical
Substances (INNs), SCT/16/3 (Sept. 1, 2006).
24. Feldman & Lobo, supra note 14.
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A proprietary name or trademark is selected by the proprietor of the
product to indicate the source of origin and quality attached to it. The
proprietary name differentiates the product from other available market
alternatives, thereby reducing consumers’ search costs. For example,
Acetaminophen is marketed under the brand name Tylenol®, comprising
of the chemical N-(4- Hydroxyphenyl)acetamide. Similarly, the antiinflammatory drug Ibuprofen is identified under its brand name as
Motrin®, which is comprised of the chemical 2-[4-(2methylpropyl)phenyl]propanoic acid.
Usually, consumers first get acquainted with the drug’s brand name,
and once the patent for the branded drug expires, the pharmaceutical
trademarks play a vital role in determining consumer choice. However,
application of trademarks by the companies in a manner that leads to
create artificial differentiation may deter fair market competition,
ultimately affecting consumer health. 25 While conveying distinctiveness
of source, a trademark also conveys, in the language of marketing, “brand
differentiation.”
IV. A STUDY OF BRAND PROLIFERATION FOR BRANDED AND BRANDEDGENERIC MARKET SEGMENTS
In 2020, the global pharmaceutical market revenue totaled $1.27
trillion U.S. dollars, 26 while total pharma advertising spending topped
$6.58 billion. 27 Drug companies’ heavy spending on marketing supports
the importance of trademarks in the pharmaceutical industry across the
globe. A branded drug company utilizes the exclusive period of patent
protection to market its drug, and spends heavily on its promotion
intending to make consumers familiar with the advertised trademark.
Thereby, upon patent expiration when generic companies enter the market
they use different trademarks, this in a way further leads to brand
proliferation for a single drug composition. Brand proliferation can also
be orchestrated by developing a new product with an existing molecule to
enhance patient convenience, improve drug efficacy and safety profile, or
find novel usage. The strategies and objectives of an innovator branded
drug company are different from the strategies implemented by the
25. Brennan, supra note 17.
26. Matej Mikulic, Global Pharmaceutical Industry—Statistics and Facts, STATISTA (Sept.
10, 2021), https://www.statista.com/topics/1764/global-pharmaceutical-industry/#dossierKeyfigures
[https://perma.cc/BF36-C4KG].
27. Beth Snyder Bulik, The Top 10 Ad Spenders in Big Pharma for 2020, F IERCE P HARMA
(Apr. 19, 2021, 3:00 AM), https://www.fiercepharma.com/special-report/top-10-ad-spenders-b i g pharma-for-2020 [https://perma.cc/54J5-27RD].
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branded-generic companies. This section aims to highlight certain
strategies that utilize trademarks to retain and promote brand equity for
branded and branded-generic products.
A. Product Line Extension and Regulation in the United States
Pharmaceutical Branded Drug Segment
During their twenty years of patent protection, patented drug, relying
on trademark protection, acquires substantial consumer loyalty for a
particular brand through aggressive advertising and free sampling. This
may get eroded by the competitive entry of generic products. To prevent
this, the innovator drug companies use different strategies that include the
use of trademarks as a marketing tool, building up clientele fidelity. One
of the popular strategies is launching multiple brands for a single API by
extending a new product line, sometimes to address a new market
segment. A few examples of such a strategy from the US pharmaceutical
industry are highlighted below in Table 1.
Table 1: Examples of Line Extensions under Two Brands.
Manufacturers

G en eri c Name

B ra n d Na me 1 &
I n d i ca ti o n
P rozac- d ep res s i o n

B ra n d Na me 2 &
I n d i ca ti o n
S arafem - p re-m en s t ru a l
d y s p h o ri c d i s o rd er
Azm acort - as t hm a
Zy b an- s m o k i n g
ces s at i on
P ros car -b en i g n
p ro s t at i c h y p erp l as i a
En t o co rt / R h i n o co rt –
al l ergy
Average – faci a
wri n k l i n g
R evat i o - P u l m o n ary
art eri al Hy p ert en s i o n
(P AH)

Eli Lilly

F l u o x et i n e

Av en t i s
Gl axoS m i t hKl i ne

Tri am ci n o l o n e
B u p ro p i o n

M erck & C o

F i nas t eri de

As t raZen ec a

B u d es o n i d e

Nas acort - al l ergi es
Wel l but ri nd ep res s i o n
P ropeci a- m al e
p at t ern b al d n es s
P ul m i cort - as t hm a

Al l erg an

Tazaro t en e

Tazorac- acne

P fi zer

S i l denafi l
C i t rat e

Vi agra- Erect i l e
Dy s fu n ct i o n

In most cases, the new brand has a distinct value proposition (quality,
functionality, etc.) that positions it above or below the existing brand for
competitive purposes, if not in a different market altogether. These
additional benefits are verified by the FDA, even though the active
ingredients in both the products may have remained the same. For
example, Eli Lilly’s patent for the antidepressant drug fluoxetine (generic
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name), popularly known as Prozac®, 28 was about to expire and its price
was also expected to fall. Consequently, the company renamed and
repackaged fluoxetine in pink and lavender capsules and launched it as
Sarafem®, with the new therapeutic use of treating Premenstrual
Dysphoric Disorder. The company even indicated to its shareholders that
the launch of Sarafem® was entwined to the company’s preparations for
“Year X,” the year patent protection runs out for Prozac. 29
The extended, exclusive patent protection along with a new line of
the product was created as a new application for the known API.
Consequently, the price of Prozac, which would have fallen due to
competition from generic versions, maintained its price stability at a
higher price even though it was the same chemical. Sarafem was
aggressively advertised directly to consumers and medical practitioners.
It is worth noting that years after the patent expiration, the price gap
between the branded and generic versions is still vast. The current price
of 20 mg Sarafem® is $22.14 per unit and $18.37 per unit for Prozac®,
whereas the generic version of the same composition is priced at $0.85
per unit. 30
In another example, Merck & Co. patented Finasteride, a drug used
for the treatment of benign prostate enlargement, an uncomfortable
condition attributed to older males that can cause additional malaises such
as kidney problems. 31 It was marketed under the brand name Proscar®.
Additional patent protection and FDA approval were sought and granted
when a new use of Finasteride for treating male pattern baldness was
identified by the company, and thereafter marketed under the brand name
Propecia®. Even after the patent’s expiration in 2013, the current market

28. In 1998, the pharmaceutical companies spent $400 million to market and advertise
antidepressants. Of that, $150 million was spent promoting Prozac. Terry Turner, Cymbalta Clinical
Trials & Development, DRUGWATCH, https://www.drugwatch.com/cymbalta/clinical-trials/
[https://perma.cc/FAA2-FCZH].
29. Shankar Vedantam, Renamed Prozac Fuels Women’s Health Debate, WASHINGTON P OST,
(Apr. 29, 2001), https://www.washingtonpost.com/archive/politics/2001/04/29/renamed-prozacfuels-womens-health-debate/b05311b4-514a-4e65-aaa5 -434cb2934271/
[https://perma.cc/ZYR7539G].
30. Fluoxetine Prices, Coupons and Patient Assistance Programs, DRUGS. COM
https://www.drugs.com/price-guide/fluoxetine#oral-tablet-10-mg
[https://perma.cc/EC9B-EDBZ]
(last visited Jan. 24, 2022).
31. Benign Prostatic Hyperplasia (BPH), MAYO C LINIC https://www.mayoclinic.org/diseasesconditions/benign-prostatic-hyperplasia/symptoms-causes/syc-20370087 [https://perma.cc/QW4FUJJ6] (last visited Jan. 24, 2022).
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price of 5 mg Proscar® is around $5 per unit, 32 and the price of 1 mg
Propecia® is around $4 per unit 33 ; the generic alternatives are available at
prices around $1 and $0.84 for 1 mg and 5 mg respectively. 34
A similar practice can be observed for GlaxoSmithKline’s
bupropion. The anti-depressant Wellbutrin® was given the additional
name Zyban®, indicating its new therapeutic use to help stop smoking.
The strategy of API line extension under different brand names is popular
in the innovator drug industry. This is a successful commercial strategy
because the wide advertisement for the new therapeutic use prompts
consumers to ask for specific advertised products.
For better recognition of the advertised brands the companies also
use trade dress to add a functionality of distinctive identity. One example
is AstraZeneca (AZ), which introduced a new class of medication known
as proton-pump inhibitors (“PPIs”), generically known as Omeprazole.
After obtaining a patent, it sold the drug under the proprietary name
Prilosec®. The drug was aggressively advertised under the trademark
“The Purple Pill.” 35 The drug promotions for “The Purple Pill” appeared
in every medium—on TV, the internet, and in print ads. The pill’s trade
dress comprised of the purple color; it was at the heart of this effort, which
is still under trademark protection. 36 In this way, potential consumers did
not need to recall the drug’s name. All they had to do was remember its
color. 37
In 2001, before the patent expired, the company launched a
reformulated version of Prilosec® with the same therapeutic use under the
trademark Nexium® (generically known as Esomeprazole) and marketed
it as “The New Purple Pill.” With this strategy, AZ successfully attracted

32. Proscar Prices, Coupons and Patient Assistance Programs, DRUGS. COM
https://www.drugs.com/price-guide/proscar [https://perma.cc/WT4Q-LAPL] (last visited Jan. 24,
2022).
33. Propecia Prices, Coupons and Patient Assistance Programs, DRUGS. COM
https://www.drugs.com/price-guide/propecia [https://perma.cc/5R6J-MQ44] (last visited Jan. 24,
2022).
34. Finasteride Prices, Coupons and Patient Assistance Programs, DRUGS. COM
https://www.drugs.com/price-guide/finasteride#oral-tablet-1-mg
[https://perma.cc/RQ6G-P26S]
(last visited Jan. 24, 2022).
35. THE PURPLE PILL, Registration No. 78176056.
36. The mark consists of the color(s) purple, and gold is/are claimed as a feature of the mark,
Registration No. 2980749.
37. Neil Swidey, The Costly Case of the Purple Pill—The Story of One Blockbuster Heartburn
Drug Tells You Everything You Need to Know About the High Cost of Prescription Medicine,
B OSTON GLOBE (Jan. 10, 2018) https://www.bostonglobe.com/magazine/2002/11/17/the-costly-casepurple-pill/oSiZkj5NLUWyW0elJPDdMK/story.html [https://perma.cc/J8JR-697R].
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the brand loyal Prilosec® customers to Nexium®. 38 Even after the patent
expiration of both Prilosec® and Nexium®, the current market price of the
branded drug per unit is $1.43 and $47.56 for 20 mg and 40 mg
(intravenous powder for injection), respectively, versus the generic price
of around $1.19 and $2.99 per unit, respectively.
These examples permit us to see the potential impacts of such a
marketing strategy, which affect medication accessibility and patient
safety. Extending the period of exclusivity restricts the entry of generic
drug manufacturers in the market, resulting in a lack of a of affordable
medication. The cost incurred in advertising and marketing the branded
drug during the exclusive period of patent protection pays off by gaining
the interest and loyalty of consumers. This is a crucial observation. In the
case of patent protection extension for a new use of a known drug, the
entry of generic manufacturers—even for the previously patented
formulation—gets restricted. As a result of brand proliferation, there is a
promotion of artificial product differentiation with the trademarks in the
market allowing few companies to explore the market for certain
treatments, without actually offering any therapeutic difference. In this
context, the primary question that arises is whether such strategies breach
the legal limits?
In response to this paradigm many regulatory interventions indicated
the trademark protection’s effects on the pharmaceutical market. For
instance, in a 1977 U.S. Federal Trade Commission (FTC) report
suggested that “the trademark, like the patent, might be given a limited
life” due to the social costs of trademarks in perpetuity. 39 In 2001, the
concerns were also raised by the FDA’s Associate Director for
Medications Error, Mr. Jerry Phillips. He addressed the presence of too
many “unnecessary” drug trademarks, strongly discouraged the use of
multiple trademarks by the same company for the same active ingredient,
and thereby declared a ban on multiple trademarks for one firm’s drug on
the ground of consumer safety. Though the ban was successfully

38. James G. Conley, Robert C. Wolcott & Eric Wong, AstraZeneca, Prilosec, and Nexium:
Marketing Challenges in the Launch of a Second-Generation Drug, HARV. B US. P UBL’G (EDUC.)
(Jan. 1. 2006) https://hbsp.harvard.edu/product/KEL336-PDF-ENG.
39. FTC, Staff Report on Sales, Promotion, and Product Differentiation in Two Prescription
Drug Markets 80 (Feb. 1977), https://www.ftc.gov/sites/default/files/documents/reports/salespromotion-and-product-differentiation-two-prescription-drug-markets/197702salespromo.pdf
[https://perma.cc/BCQ8-Y482].

Published by IdeaExchange@UAkron, 2022

13

Akron Law Review, Vol. 55 [2022], Iss. 2, Art. 3

372

AKRON LAW R EVIEW

[55:359

challenged by stakeholders, it later became one of the criteria for drug
name review. 40
However, in 2002, the FDA Centre for Biologics Evaluation and
Research (CBER) released the procedure related to the review of dual
trademarks. The CBER Manual related to “Review of CBER Regulated
Product Proprietary Names” restricted the approval of a proposed
proprietary name that uses “a different name for an essentially identical
product for a different indication.” 41 CBER expressed concern about
double dosing where healthcare practitioners and patients may not
perceive the similarity of the two products with different names. It also
speculated that “the use of different names for the same product may pose
problems in the collection and management of adverse drug reaction
reports.” 42
Thereafter, the evaluation of dual proprietary name is performed as
the part of a “proprietary name review.” For example, while approving Eli
Lilly’s drug Tadalafil under the proposed propriety name Adcirca®, the
FDA conducted the proprietary name risk assessment for the use of dual
names for the same API. Since Eli Lilly was marketing Tadalafil under
the dual trademarks Cialis® and Adcirca®, the use of one API by a single
company under different proprietary names indicated the chance of
potential for concomitant administration of Cialis® and Adcirca®. 43 Errors
of this type may remain undetectable because patients and practitioners
may not realize that the products contain the same API. There is no past
reporting of such medication error that resulted in an adverse outcome
because a patient was prescribed both products.
Meanwhile, the FDA also acknowledged that the medication errors
are under-reported, so a negative search does not guarantee that
concomitant therapy has not occurred. 44 Based on studies conducted by
medical officers, it was found that doses up to 100 mg of Tadalafil would
not cause any adverse effect on the body. On this basis, the marketing of
the product with two different names were allowed. Thereby it was
40. Best Practices in Developing Proprietary Names for Human Prescription Drug Products;
Guidance
for Industry
Availability, 85 Fed. Reg. 79189
(Dec.
4,
2020)
https://www.federalregister.gov/documents/2020/12/09/2020-27058/best-practices-in-developingproprietary-names-for-human-prescription-drug-produ cts-guidance-fo r.
41. FDA Limits on Dual Trademarks Tread on Patient Safety and Law, Reed Smith (Apr. 25,
2003) www.reedsmith.com/en/perspectives/2003/04/fda-limits-on-dual-trademarks-tread -on-pati ent saf [https://perma.cc/B7FF-6HG7].
42. Id.
43. Center For Drug Evaluation and Research, Food and Drug Administration, Application
Number: 22-332, Propritory Name Review(s) ( 2009).Error! Hyperlink reference not valid.
44. Id.
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advised in the report that the applicants educate healthcare practitioners
and patients to ensure substantial post-marketing education of prescribers,
emergency personnel, and patients about concurrent use of their same API
drugs.
Currently, the FDA allows dual proprietary names but only on a caseby-case basis. The case-by-case basis includes situations where two
products are to be administered using different routes of administration or
when they have different doses. Such exceptions are allowed after
considering the risk of medication errors to a population taking the
medication for a second indication. 45 Interestingly, the practice of brand
proliferation for the same medicinal product using trademarks is not
merely restricted to innovation-based companies but has become a
common practice in the branded-generic segment of pharmaceutical
products too.
B. Product Line Extension and Regulation in the Indian Pharmaceutical
Branded-Generic Drug Segment
India is one of the largest generic drug providers in the global
pharmaceutical market, and its pharmaceutical industry categorically
holds a dominant position for branded generics. 46 Since India’s
pharmaceutical market is unstructured and lacks drug name regulation,
the practice of using multiple trademarks for one drug has become a
regular industry practice. 47 According to a market study on the
pharmaceutical sector conducted by the Competition Commission of India
(CCI), there were 47,478 brands associated with 2,871 formulations in the
pharmaceutical market in India between August 2019 and July 2020,
averaging 17 brands for every formulation. 48 One of the most commonly
used combination-drugs from the anti-diabetes category, namely
glimepiride 2mg +metformin 500 mg tablet remains the top pick in the
industry, with about 137 brands from 120 companies in the market. 49
Taking cues from innovator drug companies that have adopted a similar

45. FDA Limits on Dual Trademarks Tread on Patient Safety and Law, supra note 36.
46. The Indian Pharmaceutical Industry, India Brand Equity Foundation (Jan. 23, 2022)
https://www.ibef.org/industry/pharmaceutical-india.aspx [https://perma.cc/T5T6-GA4L].
47. Tiwari Kuhu & Bhattacharya S. Niharika, Judicial Navigation of Drug Name Regulation in
India, 26 J. Intell. Prop. Rts. 269, 269–276 (2021).
48. Market Study on the Pharmaceutical Sector in India: Key Findings and Observations
(2021),
http://cci.gov.in/sites/default/files/whats_newdocument/Market-Study-on-the—
Pharmaceutical—Sector-in-India.pdf [https://perma.cc/U6WA-APJP].
49. Id. at 7.
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strategy of using multiple brands for one formulation, the branded-generic
manufacturers seems to follow the same path.
On the other hand, one may seek to justification of brand
proliferation through the lens of the rule of demand and supply. As per the
rule, if the supply of drugs with brand proliferation increases and demand
stays the same, the price must go down. Thus, as per this rule the
consumers must gain the benefit from competitive prices. Hence to verify
this hypothesis, the authors of this paper, have compared the price of
certain branded generic products, represented in Table 2. We analyzed
two and three brands marketed by a single drug company along with their
respective prices. As shown in the table, the maximum price difference
between two products from the same company is INR 37.93, which is
equivalent to $0.51, a nominal difference. This shows that the practice of
using multiple trademarks for a single drug formulation merely enhances
the brand equity of the company that consequently creates artificial
product differentiation. However, when compared with branded drugs, it
can be observed that competition in the case of branded drugs is grounded
on comparative quality.
Table 2: Brand Differentiation of Drugs with Price

Brand
Brand Name 2
Name 1 and
and Price
Price

Company

Cetirizine HCL

Sun Pharma
Laboratory
Ltd.

Cerzin® (10
mg-10 Tab)
MRP - Rs.
2.31

Cetrizet® (10
mg- 10 Tab)
MRP - Rs.
20.21)

Stanhist® (10
mg- 10 Tab)
MRP - Rs.
15.58)

Rs. 17.9

Cipla Ltd.

Alerid® (10
mg- 10 Tab)
MRP - Rs.
18.49)

Cetcip Tablet®
(10 mg- 10
Tab) MRP - Rs.
18.50)

Okacet Tablet®
(10 mg- 10
Tab) MRP Rs. 18.50)

Nominal
Difference

Lansoprazole (30 Cipla Ltd.
mg) (PR)

Lansec® (30
capsule)
MRP Rs.
67.50)

Lanzol™ (30
capsule) MRP
Rs. 76.50)

____

Rs. 9

Cetirizine HCL
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Amoxycillin/
Clavulanic acid
500/125 mg

Abbott India

Fightox (625
mg Tablet
10s) MRP
Rs. 149.44

Megamox Cv
(625 mg Tablet
10s) MRP Rs.
157.02

Glimepiride/
Metformin (PR)

Lupin Ltd.

Gluconorm G2
Glador M2
(15Tab) PR
(15 Tab)
MRP Rs.
MRP 216.95
179.02

375

Cosymoxyl
(625 mg Tablet
10s) MRP
155.61

Rs. 7.58

___

Rs. 37.93

Quality does not seem to be the ground of differentiation for the
branded-generic drugs, which possess the same active ingredients as the
originator medicine regardless of their brand names. Each drug also
passes through the same assessment procedure and is therefore expected
to be interchangeable or identical in terms of nonprice parameters, such
as safety and efficacy. The market study conducted by the CCI indicated
three underlying factors that contributed to the primacy of brand
competition in generics: (1) elements that design information asymmetry
regarding drugs vis-a-vis consumers of drugs; (2) unobservable quality of
drugs; and (3) prescription of drugs by brand names rather than by generic
names. In absence of technical understanding, consumers are not in a
favorable position to make an informed choice and the quality and
efficacy of drugs is intrinsically unobservable. Instead, consumers follow
doctors’ prescriptions, which are often influenced by aggressive brand
promotion from pharmaceutical companies. Such brand promotion
evokes the perception of the price-quality correlation, despite the lack of
any quality difference between different branded-generic and unbranded
generic versions of the same molecule. This ultimately affects the
economic interest of consumers by reducing the price elasticity of
demand.
Consequently, the use of trademarks can be observed as merely a tool
for pharmaceutical companies to create artificial product differentiation
to be able to command a brand premium on prices and still sustain high
shares in the domestic market. 50 Since the brand names of generic drugs
can hardly signal quality, several prominent players who market these
brands often get their products manufactured through third–party or
contract manufacturing, and the same third-party manufacturer accepts
orders from multiple pharma companies. As far as the quality variance in

50. Competition Commission of India (CCI), Policy Note: Making Markets Work for
Affordable
Healthcare (Oct. 2018), https://www.cci.gov.in/sites/default/files/event%20document/POLICY_NO
TE_0.pdf?download=1 [https://perma.cc/HXU7-JGLX].
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drugs is concerned, it is attributed to the non-uniform enforcement of
quality standards across states.
Therefore, the CCI report recommended certain solutions, including
the introduction of an institutional quality signaling mechanism. An
example is the incorporation of standard-compliance marks, providing
confidence to consumers and physicians for generic name prescriptions
and improving the public perception of generic drugs as a whole. There is
also a need for structural modification of India’s drug regulatory system
to confirm a uniform and effective implementation of existing quality
standards, and create a national digital drug databank for more
transparency regarding the standards followed for drug approval by the
authorities.
V. CONCLUSION
Thus, many questions arise among scholars regardless of their views
and approaches: does branding in the pharmaceutical industry work, since
marketable drugs are approved through the same regulatory process? Do
trademarks help the consumers identify and differentiate the correct
medication or do they just create an artificial product differentiation?
It can be concluded by the authors that the function of
pharmaceutical trademarks has shifted from preventing consumer
confusion to enhancing brand equity with multiple brands on the portfolio,
thereby expanding the profit through product differentiation. Trademark
rights gain additional importance because they offer a monopolistic way
to capitalize on the brand image and recoup the substantial investment
made in a medicine’s creation. Since many companies, both innovator and
generic drug companies, have joined the race to develop differentiated
drug products, finding new clinical uses of a drug has enhanced the scope
for creating a new market and extended its market life. In a way, product
differentiation provides a first-line treatment to manage the life cycle of a
molecule facing patent extinction owing to generic competition.
Therefore, after studying the use of trademarks in the two different
segments of the pharmaceutical industry and linking the cited case studies
for innovative drug industry along with scholarship on the subject matter,
the economic theory of Landes and Posner 51 seems appropriate to the
extent where chemically similar formulations are marketed by different
proprietors. However, when one single drug composition is marketed by
a single proprietor under multiple trademarks and aggressive advertising,
51. Landes & Posner, supra note 7.
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it leads to artificial product differentiation, which invalidates their theory.
Such differentiation may not have a fatal impact on patients’ health, but
using brand, rather than generic names for medications can increase health
care costs by restricting the entry of the generic drugs into the market. To
regulate this, trademark applications bearing multiple brand names should
be subject to a strict scrutiny analysis as part of drug name regulation.
The purpose of using trademarks by the branded-generic companies
seems to be only for maximizing profits on a generic drug, though the
underlying intent of generics is presumably to provide better access to
medicine.
Having this in mind, lessons of the renowned scholar Barton Beebe
must be taken into consideration. 52 Beebe acknowledged two types of
distinctiveness: brand distinctiveness and distinctiveness of origin. While
the first differentiates the brands, the second indicates the origin of the
product. Therefore, in this circumstance, the recommendation given by
CCI towards adoption of standard-compliance marks for branded generic
drugs seems well justified. As proposed by CCI, the creation of standardcompliance marks for all the branded-generic drugs will solve the problem
to an extent. In that scenario, the necessity for obtaining or using a variety
of trademarks would not be in existence, since the quality of all the
marketable drugs would be assured by the standard-compliance marks.

52. Beebe, supra note 11.
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